Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
- Conditions
- Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00083226
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00004002
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00080405
PS-341 in Treating Patients With Hematologic Cancer
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006098
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
- Conditions
- Gastrointestinal Carcinoid TumorIslet Cell Tumor
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: bortezomibDrug: fluorouracilDrug: leucovorin calciumOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00007878
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
- Conditions
- Blastic Phase Chronic Myelogenous LeukemiaChildhood Acute Promyelocytic Leukemia (M3)Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00077467
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
- Conditions
- Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- Drug: bortezomibOther: laboratory biomarker analysis
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00077441
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Salivary Gland CancerSalivary Gland Adenoid Cystic CarcinomaStage III Adenoid Cystic Carcinoma of the Oral CavityStage III Salivary Gland CancerStage IV Adenoid Cystic Carcinoma of the Oral CavityStage IV Salivary Gland Cancer
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00077428
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
PS-341 in Treating Patients With Metastatic Malignant Melanoma
- Conditions
- Stage IV MelanomaRecurrent Melanoma
- Interventions
- Drug: bortezomibOther: laboratory biomarker analysis
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00024011
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.